Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34+ hematopoietic progenitors

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3198-3204

  Pilarski, Linda M ^a   Belch, Andrew R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOGRAFT; BONE LESION; BONE MARROW; CANCER GRAFT; CONTROLLED STUDY; CRYOPRESERVATION; DIABETES MELLITUS; HEMATOPOIETIC STEM CELL; IMMUNE DEFICIENCY; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD34; BONE MARROW; BONE MARROW PURGING; BONE NEOPLASMS; CRYOPRESERVATION; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOMAGNETIC SEPARATION; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM CIRCULATING CELLS; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE PRESERVATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 0036794974     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Szczepek, A. J., Seeberger, K., Wizniak, J., Mant, M. J., Belch, A. R., and Pilarski, L. M. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood, 92: 2844-2855, 1998.
2. Billadeau, D., Ahmann, G., Greipp, P., and Van Ness, B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med., 178: 1023-1031, 1993.
3. Bakkus, M. H. C., Van Riet, I., Van Camp, B., and Thielemann, K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br. J. Hematol., 87: 68-74, 1994.
4. Corradini, P., Boccadoro, M., Voena, C., and Pilieri, A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to c-mu sequence in immunoglobulin (IgG) and IgA secreting multiple myelomas. J. Exp. Med., 178: 1091-1096, 1993.
5. Reiman, T., Seeberger, K., Taylor, B. J., Szczepek, A. J., Hansen, J., Mant, M. J., Coupland, R. W., Belch, A. R., and Pilarski, L. M. Persistent pre-switch myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood, 98: 2791-2799, 2001.
6. Pilarski, L. M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R. W., and Belch, A. R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 95: 1056-1065, 2000.
7. Pilarski, L. M., Seeberger, K., Keats, J. J., Taylor, B. J., Coupland, R. W., and Belch, A. R. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD SCID mice. Exp. Hematol., 30: 221-228, 2002.
8. Pilarski, L. M., and Belch, A. R. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood, 83: 724-736, 1994.
9. Mitterer, M., Oduncu, F., Lanthaler, A. J., Drexler, E., Amaddi, G., Fabris, P., Emmerich, B., Coser, P., and Straka, C. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. Br. J. Haematol., 106: 737-743, 1999.
10. Straka, C., Mitterer, M., Oduncu, F., Drexler, E., Schnabel, B., Suttmann, I., Bleicher, R., Langenmayer, I., Buhlmann, H., Auchter, K., Bartl, R., Lamerz, R., Dietzfelbinger, H., Sandherr, M., Starck, M., Fischer, N., Gesierich, W., Brack, H., Nerl, C., Coser, P., and Emmerich, B. Immunomagnetic ex vivo B cell purging in multiple myeloma: a prospective comparative trial. Blood, 96: 583a-583a, 2000.
11. Thunberg, U., Banghagen, M., Bengtsson, M., Christenssen, L. D., Geilser, C. H., Gimsing, P., Lenhoff, S., Mortensen, B. T., Olafsson, T., Simonsson, B., Anderson, N. S., Sundstrom, C., Swedin, A., Sallstrom, J. F., Thuresson, B., Westin, J., and Carlson, K. Linear reduction of clonal cells in stem cell enriched grafts in transplanted myeloma. Br. J. Haematol., 104: 546-552, 1999.
12. Gazitt, Y., Reading, C. C., Hoffman, R., Wickrema, A., Vesole, D., Jagannath, S., Condino, J., Lee, B., Barlogie, B., and Tricot, G. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood, 86: 381-389, 1995.
13. Lemoli, R. M., Fortuna, A., Motta, M. R., Rizzi, S., Guidice, V., Nanetti, A., Martinelli, G., Cavo, M., Amabile, M., Manganti, S., Fogli, M., Conte, R., and Tura, S. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood, 87: 1625-1634, 1996.
14. Gahrton, G., Svensson, H., Bjorkstrand, B., Apperly, J., Carlson, K., Cavo, M., Ferrant, A., Fouillard, L., Gratecos, N., Gratwohl, A., Guihot, F., Lambertenghi Desliliers, G., Ljungman, P., Masszi, T., Milligan, D. W., Powles, R. L., Reiffers, J., Samson, J. D., Stoppa, A. M., Vernant, J. P., Volin, L., and Wallvik, J. Syngeneic transplantation in multiple myeloma-a case matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplant., 24: 741-745, 1999.
15. Bensinger, W. I., Demirer, T., Buckner, C. D., Appelbaum, F. R., Storb, R., Lilleby, K., Weiden, P., Bluming, A. Z., and Fefer, A. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant., 18: 527-531, 1996.
16. Johnsen, H. E., Hutchings, M., Taaning, E., Rasmussen, T., Knudsen, L. M., Hansen, S. W., Andersen, H., Gaarsdal, E., Jensen, L., Nikolajsen, K., Kjaesgard, E., and Hansen, N. E. Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation. Bone Marrow Transplant., 24: 1329-1336, 1999.
17. Pilarski, L. M., Pruski, E., Wizniak, J., Paine, D., Seeberger, K., Mant, M. J., Brown, C. B., and Belch, A. R. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood, 93: 2918-2927, 1999.
18. Pilarski, L. M., Giannakopoulos, N. V., Szczepek, A. J., Masellis, A. M., Mant, M. J., and Belch, A. R. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin. Cancer Res., 6: 585-596, 2000.
19. Szczepek, A. J., Bergsagel, P. L., Axelsson, L., Brown, C. B., Belch, A. R., and Pilarski, L. M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood, 89: 1824-1833, 1997.
20. Gazitt, Y., Tian, E., Barlogie, B., Reading, C. C., Vesole, D., Jagannath, S., Schnell, J., Hoffman, R., and Tricot, G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood, 87: 805-811, 1996.
21. Dyson, P. G., Horvath, N., Joshua, D., Barrow, L., Van Holst, N. G., Brown, R., Gibson, J., and To, L. B. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high dose therapy and mobilization in multiple myeloma. Bone Marrow Transplant., 25: 1175-1184, 2000.
22. RootsWeiss, A., Papadimitriou, C., Serve, H., Hoppe, B., Koenigsmann, M., Reufi, B., Oberberg, D., Thiel, E., and Berdel, W. E. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Bone Marrow Transplant., 19: 1239-1246, 1997.
23. Vescio, R. A., Schiller, G. J., Stewart, A. K., Ballester, O., Noga, S., Freytes, C., Staudtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Mecharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., DiPersio, J., Anderson, K. C., and Berenson, J. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood, 93: 1858-1868, 1999.
24. Lemoli, R. M., Martinelli, G., Zamagni, E., Motta, M. R., Rizzi, S., Terragna, C., Rondelli, R., Ronconi, S., Curti, A., Bonifazi, F., Tura, S., and Cavo, M. Engraftment, clinical and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high dose chemotherapy. Blood, 95: 2234-2239, 2000.
25. Stewart, A. K., Vescio, R. A., Schiller, G., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Beyunes, M., Jacobs, C., Berenson, R., White, M., DiPersio, J., Anderson, K. C., and Berenson, J. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall progression free survival after high dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin. Oncol., 19: 3771-3779, 2001.
26. Vescio, R. A., Hong, C. H., Cao, J., Kim, A., Schiller, G. J., Lichtenstein, A. K., Berenson, R. J., and Berenson, J. R. The hematopoietic stem cell antigen CD34 is not expressed on the malignant cells in multiple myeloma. Blood, 84: 3283-3290, 1994.
27. Latreille, J., Barlogie, B. A., Dosik, G. A., Johnson, D. A., Drewinko, B., and Alexanian, R. Cellular DNA content as a marker of human multiple myeloma. Blood 55:403-408: 81-90, 1980.
28. Montecucco, C., Riccardi, A., Merlini, G., Mazzini, G., Giordano, P., Danova, M., and Ascari, E. Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. Br. J. Cancer Clin. Oncol., 20: 81-90, 1984.